Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
TCTR |
Last refreshed on:
|
29 April 2024 |
Main ID: |
TCTR20140224006 |
Date of registration:
|
24/02/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
The effect of different groups of progestin on sleeping of menopausal women
|
Scientific title:
|
The effect of different groups of progestin on sleeping of menopausal women |
Date of first enrolment:
|
03/03/2014 |
Target sample size:
|
100 |
Recruitment status: |
Pending (Not yet recruiting) |
URL:
|
https://www.thaiclinicaltrials.org/show/TCTR20140224006 |
Study type:
|
Interventional |
Study design:
|
Randomized
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Thailand
| | | | | | | |
Contacts
|
Name:
|
Ekachai
Leeangkoonsathian |
Address:
|
Department of obstetrics and gynaecology, Maharaj Nakorn Chiang Mai Hospital
50200
Chiang Mai
Thailand |
Telephone:
|
+66891754641 |
Email:
|
excerp@gmail.com |
Affiliation:
|
Department of obstetrics and gynaecology, Maharaj Nakorn Chiang Mai Hospital |
|
Name:
|
Ekachai
Leeangkoonsathian |
Address:
|
110 Intrawaroroj Road, Sri Phum
50200
Chiang Mai
Thailand |
Telephone:
|
+66891754641 |
Email:
|
excerp@gmail.com |
Affiliation:
|
Department of obstetrics and gynaecology, Maharaj Nakorn Chiang Mai Hospital |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: New menopausal patients at Maharaj Nakorn Chiang Mai Hospital
suitable for estrogen plus progesterone treatment
Exclusion criteria: contraindication for hormone replacement therapy
recently use sleep drug
recently use psychotic drug
Age minimum:
40 Years
Age maximum:
65 Years
Gender:
Female
|
Health Condition(s) or Problem(s) studied
|
Menopausal and Postmenopausal Disorders Sleeping quality menopause climacteric progestin dydrogesterone micronized progesterone
|
Sleeping quality menopause climacteric progestin dydrogesterone micronized progesterone
|
Intervention(s)
|
1 mg 17 beta-estradiol plus 100 mg micronized progesterone oral once a day for 3 months.,1mg 17 beta-estradiol plus 10 mg dydrogesterone oral once a day for 3 months.
|
Experimental Drug,Experimental Drug
|
micronized progesterone,dydrogesterone
|
Primary Outcome(s)
|
Improving of sleeping quality (assessed by the PSQI score) Patient reported outcome using a questionnaire interview
|
Secondary Outcome(s)
|
The side effect and climacteric symptoms comparing between 2 arms. Patient reported outcome using a questionnaire interview
|
Source(s) of Monetary Support
|
Faculty of medicine, Chiang Mai University
|
Ethics review
|
Status: Submitted, approved
Approval date:
Contact:
Research Ethics Committee 4
+6653-94-6204 Ext.
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
30/04/2015 |
URL:
|
|
|
|